Journal of Bone and Mineral Metabolism

, Volume 32, Issue 4, pp 434–440 | Cite as

Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain

  • Rosj Gallicchio
  • Sabrina Giacomobono
  • Anna Nardelli
  • Teresa Pellegrino
  • Vittorio Simeon
  • Domenico Gattozzi
  • Francesca Maddalena
  • Pierpaolo Mainenti
  • Giovanni Storto
Original Article
  • 337 Downloads

Abstract

We evaluated the pain response and daily discomfort in patients suffering from a borderline degree of bone pain due to breast or lung cancer bone metastases, who had undergone early palliative radionuclide treatment. The results were compared with those from patients who had received standard analgesic therapy. Twenty-one patients (65.7 ± 3 years; 17 women) with metastatic bone cancer underwent samarium-153 (Sm-153) ethylene diamine tetramethylene phosphonate (EDTMP) administration (group A) and 18 patients (64.3 ± 8 years; 16 women) continued to receive standard analgesics (group B; control group). The patients kept a daily pain diary assessing both their discomfort and the pain at specific sites by means of a visual analog scale, rating from 0 (no discomfort–no pain) to 10 (worst discomfort–pain). These diaries were reviewed weekly for 2 months and three physicians rated the pain response on a scale from −2 (considerable deterioration) to +2 (considerable improvement). Baseline characteristics were similar in both groups. The reduction of total discomfort and of bone pain in group A was significantly greater compared to group B (p < 0.0001). A significant improvement of clinical conditions was observed in group A, where the physician rate changed from −1 to 1, compared to group B in which the rate changed from −1 to 0. Sm-153 EDTMP therapy can be considered for patients with bone pain from breast and lung cancer in advance, i.e., before the establishment of severe pain syndrome.

Keywords

Low degree bone pain Palliation Radionuclide therapy Sm-153 EDTMP 

References

  1. 1.
    Reddi AH, Roodman D, Freeman C, Mohla S (2003) Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 18:190–1944PubMedCrossRefGoogle Scholar
  2. 2.
    Nielsen OS, Munro AJ, Tannock IF (1991) Bone metastases: pathophysiology and management policy. J Clin Oncol 9:509–524PubMedGoogle Scholar
  3. 3.
    Coleman RE, Rubens RD (1987) The clinical course of bone metastases in breast cancer. Br J Cancer 55:61–66PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biol 91:718–729Google Scholar
  5. 5.
    Hortobagyi GN (2002) Novel approaches to the management of bone metastases in patients with breast cancer. Semin Oncol 29:134–144PubMedCrossRefGoogle Scholar
  6. 6.
    Burris HA 3rd, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S (2013) Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. Cancer 119:1908–1915PubMedCrossRefGoogle Scholar
  7. 7.
    Perry CM, Figgitt DP (2004) Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 64:1197–1211PubMedCrossRefGoogle Scholar
  8. 8.
    Soloway MS, Ishikawa S, van der Waag R, Todd B (1989) Prognostic factors in patients with advanced prostate cancer. Urology 33:53–56PubMedCrossRefGoogle Scholar
  9. 9.
    Kassamali RH, Ganeshan A, Hoey ET, Crowe PM, Douis H, Henderson J (2011) Pain management in spinal metastases: the role of percutaneous vertebral augmentation. Ann Oncol 22:782–786PubMedCrossRefGoogle Scholar
  10. 10.
    Body JJ (1992) Bone metastases and tumor-induced hypercalcaemia. Curr Opin Oncol 4:624–631PubMedCrossRefGoogle Scholar
  11. 11.
    Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of 153 Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33:1583–1591PubMedCrossRefGoogle Scholar
  12. 12.
    Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P, Quadramet 424Sm10/11 Study Group (2004) Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63:940–945PubMedCrossRefGoogle Scholar
  13. 13.
    Serafini AN (2000) Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastasis. Cancer 88:2934–2939PubMedCrossRefGoogle Scholar
  14. 14.
    Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16:1574–1581PubMedGoogle Scholar
  15. 15.
    Sciuto R, Maini CL, Tofani A, Fiumara C, Scelsa MG, Broccatelli M (1996) Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun 17:799–804PubMedCrossRefGoogle Scholar
  16. 16.
    Ron IG, Stav O, Vishne T, Evan-Sapir E, Soyfer V, Agai R, Cherny N, Kovner F (2004) The correlation between palliation of bone pain by intravenous strontium-89 and external beam radiation to linked field in patients with osteoblastic bone metastases. Am J Clin Oncol 27:500–504PubMedCrossRefGoogle Scholar
  17. 17.
    Sciuto R, Festa A, Rea S, Pasqualoni R, Bergomi S, Petrilli G, Maini CL (2002) Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med 43:79–86PubMedGoogle Scholar
  18. 18.
    Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M (2006) Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases. Bone 39:35–41PubMedCrossRefGoogle Scholar
  19. 19.
    Hess G, Barlev A, Chung K, Hill JW, Fonseca E (2012) Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer. Radiat Oncol 7:168PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR (1993) Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34:1839–1844PubMedGoogle Scholar
  21. 21.
    Pandit-Taskar N, Batraki M, Divgi CR (2004) Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 45:1358–1365PubMedGoogle Scholar
  22. 22.
    Mincey BA, Perez EA (2004) Advances in screening, diagnosis, and treatment of breast cancer. Mayo Clin Proc 79:810–816PubMedCrossRefGoogle Scholar
  23. 23.
    Decroisette C, Galerneau LM, Hominal S, Chouaid C (2013) Epidemiology, management and cost of bone metastases from lung cancer. Rev Mal Respir 30:309–315PubMedCrossRefGoogle Scholar
  24. 24.
    Zhang H, Tian M, Li S, Liu J, Tanada S, Endo K (2003) Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm 18:719–726PubMedCrossRefGoogle Scholar
  25. 25.
    Reich CD (2003) Advances in the treatment of bone metastases. Clin J Oncol Nurs 7:641–646PubMedCrossRefGoogle Scholar
  26. 26.
    Coronado M, Redondo A, Coya J, Espinosa E, Couto RM, Zamora P, Marin MD, Castelo B, Lillo ME, Frutos L, Barón MG, Curto LM (2006) Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease. Clin Nucl Med 31:605–610PubMedCrossRefGoogle Scholar
  27. 27.
    Serafini AN (2001) Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 45:91–99PubMedGoogle Scholar
  28. 28.
    Berger M, Grignani G, Giostra A, Ferrari S, Ferraresi V, Tamburini A, Cefalo G, Carnevale-Schianca F, Vassallo E, Picci P, Pagano M, Aglietta M, Pellerito RE, Fagioli F (2012) 153 samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann Oncol 23:1899–1905PubMedCrossRefGoogle Scholar
  29. 29.
    Lewington VJ (2005) Bone-seeking radionuclides for therapy. J Nucl Med 46:38S–47SPubMedGoogle Scholar
  30. 30.
    Turner JH, Claringbold PG (1991) A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 27:1085–1086Google Scholar
  31. 31.
    Storto G, Gallicchio R, Pellegrino T, Nardelli A, De Luca S, Capacchione D, Sirignano C, Pace L (2013) Impact of 18F-Fluoride PET-CT on implementing early treatment of painful bone metastases with Sm-153 EDTMP. Nucl Med Biol 40:518–523PubMedCrossRefGoogle Scholar
  32. 32.
    Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M, Yellen SB, Winicour P, Brannon J (1993) The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 11:570–579PubMedGoogle Scholar
  33. 33.
    Hwang SS, Chang VT, Kasimis B (2002) Dynamic cancer pain management outcomes: the relationship between pain severity, pain relief, functional interference, satisfaction and global quality of life over time. J Pain Symptom Manage 23:190–200PubMedCrossRefGoogle Scholar
  34. 34.
    Storto G (2009) Radionuclide Therapy. In: Kardamakis D, Vassiliou V, Chow E (eds) Bone metastases: a translational and clinical approach, vol 12. Springer, Netherlands, pp 321–341CrossRefGoogle Scholar
  35. 35.
    Sartor O (2004) Overview of samarium Sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol 6:S3–S12PubMedCentralPubMedGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan 2013

Authors and Affiliations

  • Rosj Gallicchio
    • 1
  • Sabrina Giacomobono
    • 1
  • Anna Nardelli
    • 2
  • Teresa Pellegrino
    • 2
  • Vittorio Simeon
    • 1
  • Domenico Gattozzi
    • 3
  • Francesca Maddalena
    • 1
  • Pierpaolo Mainenti
    • 2
  • Giovanni Storto
    • 1
  1. 1.Istituto di Ricovero e Cura Carattere Scientifico, Centro di Riferimento Oncologico di BasilicataRionero in VultureItaly
  2. 2.Institute of Biostructure and BioimagesNational Council of ResearchNaplesItaly
  3. 3.University of Texas, SouthwesternDallasUSA

Personalised recommendations